A Prospective, Single-arm, Phase II Study of PD-1 Inhibitor Combined With Ifosfamide, Carboplatin, and Etoposide (ICE) in the Treatment of Relapsed/Refractory Gray Area Lymphoma
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Lymphoma
- Focus Therapeutic Use
- Acronyms PICE
- 04 May 2021 New trial record